Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Share
Cytokinetics Inc (CYTK) Director Robert Landry sold 1,000 shares on 2026-09-15, reducing his holding to 8,184 shares. The sale occurred at $72.13 per share, with the company's market cap at $9.64 billion. Over the past year, Landry sold 2,000 shares and bought none, aligning with a broader trend of 79 insider sells and 0 buys. GuruFocus values CYTK at $220.41, suggesting a possible value trap with a 0.33 price-to-GF-Value ratio.
How this was made
The 30-second read
Why it matters
The disclosed insider sale adds a negative data point for CYTK, potentially influencing short-term price action.
Market read
Insider selling at a biotech with a large valuation discount may prompt traders to reassess risk exposure.
What to watch
GuruFocus valuation suggests a deep discount; institutional guru buying may offset insider sell pressure.
Background
The article reports a Form 4 filing showing a director's recent stock sale and places it in the context of overall insider activity and valuation metrics.
Ticker impact
Director Robert Landry sold 1,000 CYTK shares on Sep 15, continuing a pattern of insider selling.
Potential short-term downside as investors interpret continued insider selling as a bearish signal.
While the dollar amount ($72k) is modest, the cumulative insider sell volume (79 shares sold, zero buys) signals a negative sentiment trend.
Market effects
Biopharma sector may see heightened scrutiny of insider activity, but no broad sector impact.
Limited to U.S. biotech investors; no regional effect.
Low global relevance; only affects CYTK shareholders.
Counterpoint
Insider selling could be unrelated personal liquidity needs; the stock remains undervalued at a 0.33 price-to-GF-Value ratio.
Key entities
- CompanyCytokinetics Inc
Biopharmaceutical company developing muscle function therapeutics.
- DirectorRobert Landry
CYTK board member who sold 1,000 shares.
